BridgeBio Pharma (BBIO) Stock Forecast & Price Target

Compare

1,294 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBIO Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

BridgeBio

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$61.79

▲(42.05%Upside)

Based on 16 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $61.79 with a high forecast of $95.00 and a low forecast of $42.00. The average price target represents a 42.05% change from the last price of $43.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","96":"$96","41.25":"$41.3","59.5":"$59.5","77.75":"$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$61.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41.25,59.5,77.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,46.79692307692308,50.81384615384616,54.830769230769235,58.84769230769231,62.86461538461539,66.88153846153847,70.89846153846153,74.91538461538462,78.93230769230769,82.94923076923078,86.96615384615384,90.98307692307692,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,44.24230769230769,45.70461538461539,47.16692307692308,48.62923076923077,50.09153846153846,51.55384615384615,53.01615384615384,54.47846153846154,55.940769230769234,57.403076923076924,58.86538461538461,60.3276923076923,{"y":61.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,42.72,42.660000000000004,42.6,42.54,42.480000000000004,42.42,42.36,42.3,42.24,42.18,42.12,42.06,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$61.79

Lowest Price Target$42.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$44

Hold

1.15%

Upside

Reiterated

06/24/25

BridgeBio Pharma benefits from strong technical momentum and positive earnings call with successful product launches and pipeline progress. However, financial performance and valuation concerns due to unprofitability and high leverage weigh heavily on the overall score.

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$95

Buy

118.39%

Upside

Reiterated

07/03/25

Cantor Fitzgerald Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Mani ForooharLeerink Partners

Leerink Partners

$53

Buy

21.84%

Upside

Reiterated

07/01/25

Strategic Financial Maneuvers and Growth Potential: BridgeBio Pharma's Path to Profitability

Danielle BrillRaymond James

Raymond James

$57

Buy

31.03%

Upside

Reiterated

06/30/25

Raymond James Remains a Buy on BridgeBio Pharma (BBIO)

David LebowitzCiti

Citi

$58

Buy

33.33%

Upside

Reiterated

06/30/25

BridgeBio Pharma (BBIO) Receives a Buy from Citi

Tiago FauthWells Fargo

Wells Fargo

$67→$76

Buy

74.71%

Upside

Reiterated

06/30/25

Analysts Are Bullish on These Healthcare Stocks: Aardvark Therapeutics, Inc. (AARD), BridgeBio Pharma (BBIO)

Jason ZemanskyBank of America Securities

Bank of America Securities

$50→$54

Buy

24.14%

Upside

Reiterated

06/27/25

BridgeBio Pharma's Promising Growth Potential Driven by Attruby and Upcoming Pivotal Readouts for Encaleret and BBP-418

Biren AminPiper Sandler

Piper Sandler

$63

Buy

44.83%

Upside

Reiterated

06/26/25

Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/24/25

BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen

Cory KasimovEvercore ISI

Evercore ISI

$70→$75

Buy

72.41%

Upside

Reiterated

06/20/25

Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)

Andy ChenWolfe Research

Wolfe Research

$49

Buy

12.64%

Upside

Initiated

06/16/25

BridgeBio initiated with an Outperform at Wolfe ResearchBridgeBio initiated with an Outperform at Wolfe Research

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$53→$56

Buy

28.74%

Upside

Reiterated

06/09/25

BridgeBio price target raised to $56 from $53 at H.C. WainwrightBridgeBio price target raised to $56 from $53 at H.C. Wainwright

Kostas BiliourisBMO Capital

BMO Capital

$37→$42

Hold

-3.45%

Downside

Reiterated

06/04/25

Hold Rating for BridgeBio Pharma Amid Competitive Pressures and Uncertain Long-term Outlook

Anupam RamaJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/27/25

BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating

Salim SyedMizuho Securities

Mizuho Securities

$53→$60

Buy

37.93%

Upside

Reiterated

05/02/25

Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$44

Hold

1.15%

Upside

Reiterated

06/24/25

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$95

Buy

118.39%

Upside

Reiterated

07/03/25

Cantor Fitzgerald Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Mani ForooharLeerink Partners

Leerink Partners

$53

Buy

21.84%

Upside

Reiterated

07/01/25

Strategic Financial Maneuvers and Growth Potential: BridgeBio Pharma's Path to Profitability

Danielle BrillRaymond James

Raymond James

$57

Buy

31.03%

Upside

Reiterated

06/30/25

Raymond James Remains a Buy on BridgeBio Pharma (BBIO)

David LebowitzCiti

Citi

$58

Buy

33.33%

Upside

Reiterated

06/30/25

BridgeBio Pharma (BBIO) Receives a Buy from Citi

Tiago FauthWells Fargo

Wells Fargo

$67→$76

Buy

74.71%

Upside

Reiterated

06/30/25

Analysts Are Bullish on These Healthcare Stocks: Aardvark Therapeutics, Inc. (AARD), BridgeBio Pharma (BBIO)

Jason ZemanskyBank of America Securities

Bank of America Securities

$50→$54

Buy

24.14%

Upside

Reiterated

06/27/25

BridgeBio Pharma's Promising Growth Potential Driven by Attruby and Upcoming Pivotal Readouts for Encaleret and BBP-418

Biren AminPiper Sandler

Piper Sandler

$63

Buy

44.83%

Upside

Reiterated

06/26/25

Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/24/25

BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen

Cory KasimovEvercore ISI

Evercore ISI

$70→$75

Buy

72.41%

Upside

Reiterated

06/20/25

Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)

Andy ChenWolfe Research

Wolfe Research

$49

Buy

12.64%

Upside

Initiated

06/16/25

BridgeBio initiated with an Outperform at Wolfe ResearchBridgeBio initiated with an Outperform at Wolfe Research

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$53→$56

Buy

28.74%

Upside

Reiterated

06/09/25

BridgeBio price target raised to $56 from $53 at H.C. WainwrightBridgeBio price target raised to $56 from $53 at H.C. Wainwright

Kostas BiliourisBMO Capital

BMO Capital

$37→$42

Hold

-3.45%

Downside

Reiterated

06/04/25

Hold Rating for BridgeBio Pharma Amid Competitive Pressures and Uncertain Long-term Outlook

Anupam RamaJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/27/25

BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating

Salim SyedMizuho Securities

Mizuho Securities

$53→$60

Buy

37.93%

Upside

Reiterated

05/02/25

Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

1 Month

xxx

Success Rate

11/21 ratings generated profit

Average Return

+10.95%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.38% of your transactions generating a profit, with an average return of +10.95% per trade.

3 Months

xxx

Success Rate

12/21 ratings generated profit

Average Return

+12.02%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +12.02% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

17/20 ratings generated profit

Average Return

+35.30%

reiterated a buy rating 15 days ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +35.30% per trade.

2 Years

xxx

Success Rate

20/21 ratings generated profit

Average Return

+88.54%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +88.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBIO has received 19 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 61.79.

Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.76 with a range of -$1.10 to -$0.34. The previous quarter’s EPS was -$0.88. BBIO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BBIO has Outperformed its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $96.22M with a range of $54.73M to $198.50M. The previous quarter’s sales results were $116.63M. BBIO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year BBIO has Outperformed its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 61.79.

What is BBIO’s upside potential, based on the analysts’ average price target?

BridgeBio Pharma Inc has 42.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBIO a Buy, Sell or Hold?

BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is BridgeBio Pharma Inc’s price target?

The average price target for BridgeBio Pharma Inc is 61.79. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $42.00. The average price target represents 42.05% Increase from the current price of $43.5.

What do analysts say about BridgeBio Pharma Inc?

BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of BBIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

BBIO Analyst Ratings

BBIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Pharma

BBIO Analyst Recommendation Trends

BBIO Financial Forecast

BBIO Earnings Forecast

BBIO Sales Forecast

BBIO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts